BNT162b2 COVID ‐19 vaccine is significantly less effective in patients with hematologic malignancies

Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

(2021) Sultan Abdul-Jawad et al.   CANCER CELL

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

(2021) Noa Dagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

(2021) Yair Herishanu et al.   BLOOD

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

(2021) Brian J. Boyarsky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

(2021) Sarah Bird et al.   Lancet Haematology

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

(2021) Alberto M Borobia et al.   LANCET

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

(2020) Yang Cao et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

(2020) F. La Rosée et al.   LEUKEMIA

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

(2020) Francesco Passamonti et al.   Lancet Haematology

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

(2020) Julio García-Suárez et al.   Journal of Hematology & Oncology

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

(2020) Lindsey E. Roeker et al.   LEUKEMIA

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

(2020) Ugur Sahin et al.   NATURE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

(2020) Abi Vijenthira et al.   BLOOD

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

(2020) Christopher Pleyer et al.   BLOOD

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Transmission among Marine Recruits during Quarantine

(2020) Andrew G. Letizia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

(2020) Sheila F. Lumley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

(2019) Kathleen M Mullane et al.   LANCET INFECTIOUS DISEASES

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

(2016) Oi-Wing Ng et al.   VACCINE

Influenza and pneumococcal vaccination in hematological malignancies: a systematic review of efficacy, effectiveness and safety

(2016) Giuseppe La Torre   Mediterranean Journal of Hematology and Infectious Diseases

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

(2011) O. E. Yri et al.   BLOOD

Efficacy of accelerated hepatitis B vaccination program in patients being actively treated for hematologic malignancies

(2007) Husnu Pullukcu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES